CSIMarket Company Name, Ticker, Competitors, else..
 
Scisparc Ltd   (NASDAQ: SPRC)
Other Ticker:  
 
    Sector • Retail    Industry • Automotive Aftermarket
   Industry • Automotive Aftermarket
   Sector • Retail
 
Price: $0.3710 $0.00 -1.067%
Day's High: $0.388 Week Perf: 3.06 %
Day's Low: $ 0.35 30 Day Perf: -29.87 %
Volume (M): 310 52 Wk High: $ 3.63
Volume (M$): $ 115 52 Wk Avg: $0.65
Open: $0.36 52 Wk Low: $0.20



 Market Capitalization (Millions $) 0
 Shares Outstanding (Millions) 0
 Employees 25
 Revenues (TTM) (Millions $) 3
 Net Income (TTM) (Millions $) 6
 Cash Flow (TTM) (Millions $) 4
 Capital Exp. (TTM) (Millions $) 0

Scisparc Ltd
Scisparc Ltd is a technology company that specializes in developing artificial intelligence solutions for the healthcare industry. The company's software and algorithms are designed to analyze complex medical data, provide insights, and assist medical professionals in making accurate diagnoses and treatment decisions. Scisparc's solutions aim to improve patient outcomes, reduce medical errors, and streamline healthcare processes. The company focuses on leveraging cutting-edge technologies like machine learning, natural language processing, and data analytics to deliver innovative and effective healthcare solutions.


   Company Address: 20 Raul Wallenberg St. Tel Aviv 6971916
   Company Phone Number: 3-7175777   Stock Exchange / Ticker: NASDAQ SPRC


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
AIMD        13.07% 
ARDX   -2.76%    
ISCO   -2.76%    
RCUS   -7.58%    
SAGE        2.21% 
SBFM   -3.08%    
• View Complete Report
   



Announcement

SciSparc Expands Horizons Update on Spin-Off of Pharmaceutical Portfolio Valued at $11.6 Million

Published Sun, Dec 29 2024 8:24 PM UTC

In a strategic move that underscores its commitment to innovation and growth in the pharmaceutical sector, SciSparc Ltd., a biotechnology firm specializing in the development of advanced clinical-stage therapies, has provided crucial updates regarding the impending spin-off of its advanced pharmaceutical portfolio into a publicly traded company. This maneuver, detailed in a ...
Merger and Acquisition

SciSparc: AutoMax Announces $13 Million First Delivery of JAC Vehicles Following Regulatory Approval for Direct Importation

Published Thu, Dec 26 2024 11:46 AM UTC

SciSparc: AutoMax Announces $13 Million First Delivery of JAC Vehicles Following Regulatory Approval for Direct Importation IntroductionTEL AVIV, Israel, Dec. 26, 2024 - In a remarkable stride for the Israeli automotive sector, SciSparc Ltd. (Nasdaq: SPRC), has announced that its partner, AutoMax Motors Ltd., a leading automotive importer and distributor in Israel, has succ...
Announcement

SciSparcs Strategic Leap FDA Approval Signals New Hope for Tourette Syndrome Treatment

Published Mon, Sep 30 2024 1:25 PM UTC

Overview of Recent DevelopmentsIn a significant advancement for the treatment of Tourette Syndrome (TS), SciSparc Ltd., a clinical-stage pharmaceutical company, has received FDA approval to initiate its pivotal Phase IIb clinical trial. This approval comes less than a month after the application was submitted, marking a swift and efficient response from regulatory authoriti...
Announcement

SciSparcs Strategic Ascendancy Enhancing Value through Innovations and Strategic Patents,

Published Thu, Sep 26 2024 1:05 PM UTC

In a series of strategic advancements, SciSparc Ltd. (Nasdaq: SPRC), a specialty clinical-stage pharmaceutical company devoted to developing therapies for central nervous system disorders and rare diseases, has made significant strides in the past few months. These milestones emphasize the company s commitment to enhancing its intellectual property portfolio, fostering innov...
Clinical Study

SciSparc Ltd FDA Sanctioned Phase IIb Clinical Trial for Tourette Syndrome Amid Financial Fluidity and Sectoral...

Published Mon, Sep 23 2024 12:17 PM UTC

The undertaking of such a pivotal study posits SciSparc Ltd at the vanguard of neurological disorder treatments, demonstrating a confluence of scientific rigour and steadfast commitment to advancing human health. The anticipation surrounding this clinical trial is palpable, as it aims to address the unmet needs of those besieged by the relentless tics and involuntary behavio...









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com